MedTrace Logo

FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging

NCT02773238 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2024-08-14

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well positron emission tomography (PET)/computed tomography (CT) and single positron emission computed tomography (SPECT)/CT imaging works in improving radiation therapy treatment in patients with stage IIB-IIIB non-small cell lung cancer. PET/CT imaging mid-way through treatment may be able to accurately show how well radiation therapy and chemotherapy are working. SPECT/CT imaging may be able to tell which parts of the lung tissue are healthier than others. Based on the result of the imaging, treatment adjustments may be made to the radiation therapy to improve survival and decrease toxicity.

Conditions

  • Stage IIB Lung Non-Small Cell Carcinoma AJCC v7
  • Stage IIIA Lung Non-Small Cell Cancer AJCC v7
  • Stage IIIB Lung Non-Small Cell Cancer AJCC v7

Interventions

PROCEDURE

Computed Tomography

Undergo FDG PET/CT

PROCEDURE

Computed Tomography

Undergo Tc-99m MAA or Tc-99m DTPA

RADIATION

Fludeoxyglucose F-18

Undergo FDG PET/CT

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Positron Emission Tomography

Undergo FDG PET/CT

RADIATION

Radiation Therapy

Undergo functional avoidance radiation therapy

PROCEDURE

Single Photon Emission Computed Tomography

Undergo Tc-99m MAA or Tc-99m Undergo Tc-99m sulfur colloid SPECT/CT

RADIATION

Technetium Tc-99m Albumin Aggregated

Undergo Tc-99m MAA SPECT/CT

RADIATION

Technetium Tc-99m Sulfur Colloid

Undergo Tc-99m sulfur colloid

Sponsors & Collaborators

Principal Investigators

  • Jing Zeng · Fred Hutch/University of Washington Cancer Consortium

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-20
Primary Completion
2023-06-01
Completion
2023-12-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02773238 on ClinicalTrials.gov